39105-39-0

Usage

Uses

Used in Pharmaceutical Industry:
3-CHLORO-1-INDAN-5-YL-PROPAN-1-ONE is used as a synthetic intermediate for the development of new pharmaceutical compounds. Its versatile chemical properties enable the creation of a wide range of drugs with potential therapeutic applications.
Used in Chemical Industry:
3-CHLORO-1-INDAN-5-YL-PROPAN-1-ONE is used as a synthetic intermediate for the production of various chemicals and materials. Its unique structure allows for the synthesis of a diverse array of compounds, making it a valuable asset in the chemical industry.
Used in Research and Development:
3-CHLORO-1-INDAN-5-YL-PROPAN-1-ONE is used as a synthetic intermediate in research and development for the exploration of new chemical reactions and the creation of novel compounds with potential applications in various fields, including pharmaceuticals, materials science, and more.

Upstream product

• 496-11-7 INDANE 
• 625-36-5 2-chloropropionyl chloride 

Downstream Products

• 14927-64-1 3,5,6,7-tetrahydro-2H-s-indacen-1-one 
• 65012-14-8 1,2,7,8-tetrahydro-asymm-indacen-3(6H)-one 
• 620592-44-1 4-nitro-3,5,6,7-tetrahydro-s-indacen-1(2H)-one 
• 2676862-01-2 3-(difluoromethyl)-1,2,3,5,6,7-hexahydro-s-indacen-4-amine 
• 2676861-99-5 8-nitro-1,2,3,5,6,7-hexahydro-s-indacene-1-carbaldehyde 
• 2676865-19-1 2-(methoxymethyl)-4-nitro-1,2,3,5,6,7-hexahydro-s-indacene 
• 2676865-18-0 (4-nitro-1,2,3,5,6,7-hexahydro-s-indacen-2-yl)methanol 
• 2676865-17-9 ethyl 4-nitro-1,2,3,5,6,7-hexahydro-s-indacene-2-carboxylate 
• 2676864-15-4 3-(((tert-butyldimethylsilyl)oxy)methyl)-1,2,3,5,6,7-hexahydro-s-indacen-4-amine 
• 2676864-14-3 (8-amino-1,2,3,5,6,7-hexahydro-s-indacen-1-yl)methanol 
• 2676863-31-1 8-nitro-3,5,6,7-tetrahydro-2H-spiro[s-indacene-1,1’-cyclopropane] 
• 2676863-23-1 racemic 3-(trifluoromethyl)-3-((trimethylsilyl)oxy)-1,2,3,5,6,7-hexahydro-s-indacen-4-amine 
• 2676863-22-0 racemic 8-amino-1-(trifluoromethyl)-1,2,3,5,6,7-hexahydro-s-indacen-1-ol 
• 2676863-21-9 racemic 8-nitro-1-(trifluoromethyl)-1,2,3,5,6,7-hexahydro-s-indacen-1-ol 

Relevant academic research and scientific papers

SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS

Described herein are compounds of Formula (I), Formula (I-A), and Formula (I-B), solvates thereof, tautomers thereof, and pharmaceutically acceptable salts of the foregoing, Further described herein are methods of inhibiting NLRP3 using said compounds, and methods of and compositions useful in treating NLRP3-dependent disorders.

MACROCYCLIC SULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS

The present invention relates to macrocyclic compounds, such as macrocyclic sulfonyl ureas. The present invention further relates to associated salts, solvates, prodrugs and pharmaceutical compositions and to the use of such compounds in the treatment and

NOVEL PROCESSES

The present invention relates to processes of preparing N- ((1,2,3,4,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1H- pyrazole-3-sulfonamide and salts thereof. The present invention further relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.

AMINO HETEROCYCLIC COMPOUNDS AND USES THEREOF

The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory, and autoimmune diseases and cancers.

NLRP3 INHIBITORS

The present application relates to compounds with NLRP3inhibitory activity and to associated salts, solvates, prodrugs and pharmaceutical compositions. The present application further relates to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3inhibition.

Discovery of N-Cyano-sulfoximineurea Derivatives as Potent and Orally Bioavailable NLRP3 Inflammasome Inhibitors

NLRP3 inflammasome mediated release of interleukin-1β (IL-1β) has been implicated in various diseases. In this study, rationally designed mimics of sulfonylurea moiety were investigated as NLRP3 inhibitors. Our results culminated into discovery of series of unprecedented N-cyano sulfoximineurea derivatives as potent NLRP3 inflammasome inhibitors. Compound 15 (IC50 = 7 nM) and analogues were found to be highly potent and selective NLRP3 inflammasome inhibitor with good pharmacokinetic profile. These effects translate in vivo, as 15, 29, and 34 significantly inhibit NLRP3 dependent IL-1β secretion in mice.

NLRP MODULATORS

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein, useful to treat connected to the modulation of NRLP3.

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured (Formula A) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: (Formula AA) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.